Krebstherapie – Neue Aspekte zur neoadjuvanten Therapie bei Malignomen des oberen GITs

• Literatur

• 1 Moehler M, Al-Batran SE et al. German S3-guideline „Diagnosis and treatment of esophagogastric cancer“. Z Gastroenterol 2011; 49: 461-531
• 2 Mönig SP, Meyer HJ, Allum WH et al. Third international conference of the European Union Network of Excellence on gastric and esophagogastric cancer, Cologne, Germany, June 2012. Gastric Cancer 2014; [Epub ahead of print]
• 3 Messager M, Lefevre JH, Pichot-Delahaye V et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011; 254: 684-693
• 4 Heger U, Blank S, Wiecha C et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?. Ann Surg Oncol 2014; 21: 1739-1748
• 5 Meyer HJ, Hölscher AH et al. Current S3 guidelines on surgical treatment of gastric carcinoma. Chirurg 2012; 83: 31-37
• 6 Lordick F, Hölscher AH, Haustermans K et al. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013; 398: 177-187
• 7 Sjoquist KM, Burmeister BH, Smithers BM. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692
• 8 van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
• 9 van Heijl M, van Lanschot JJ, Koppert LB et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus [CROSS]. BMC Surg 2008; 8: 21
• 10 Thuss-Patience P, Kutup A, Eble M. Adenokarzinome des Magens und gastroösophagealen Übergangs – Neoadjuvante und adjuvante Therapie. Der Onkologe 2013; 5: 371-379
• 11 Allum WH, Stenning SP, Bancewicz J et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067
• 12 Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721
• 13 Schumacher C, Gretschl S, Lordick F et al. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin Oncol 2010; 28: 5210-5218
• 14 Piessen G, Messager M, Leteurtre E et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009; 250: 878-887
• 15 Piessen G, Messager M, Le Malicot K et al. Phase II / III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002. BMC Cancer 2013; 13: 281
• 16 Mönig SP, Zirbes TK, Schröder W et al. Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol 1999; 173: 365-367
• 17 Mönig SP, Schröder W, Baldus SE et al. Preoperative lymph-node staging in gastrointestinal cancer-correlation between size and tumor stage. Onkologie 2002; 25: 342-344
• 18 Ruol A, Rizzetto C, Castoro C et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?. Ann Surg 2010; 252: 788-796
• 19 Kim JY, Correa AM, Vaporciyan AA et al. Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome?. Ann Thorac Surg 2012; 93: 207-212
• 20 Chiu CH, Chao YK, Chang HK et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?. Ann Surg Oncol 2013; 20: 4245-4251
• 21 Martin LW. What is the optimal interval between chemoradiation and esophagectomy?. Semin Thorac Cardiovasc Surg 2012; 24: 87-89